Search Results
Mark Kris, MD: Antiangiogenic Therapy in NSCLC
The Current Role for Antiangiogenic Therapy for NSCLC
Dr. Kris Discusses Role of Antiangiogenesis in Lung Cancer
Dr. Mark Kris on Immunotherapy and Frontline Options for Patients With NSCLC
Mark Socinski, MD: Antiangiogenic Therapy in NSCLC
Using Antiangiogenic Therapy in NSCLC in the Future
Using Antiangiogenic Therapy in Stage 4 NSCLC
Rationale Behind Antiangiogenic Therapy in NSCLC
Antiangiogenic Therapy in NSCLC
Sequencing and Combining Therapies with Antiangiogenic Monoclonal Antibodies
Novel Trials of Immunotherapy Combinations for NSCLC
Dr. Mark G. Kris on Side Effects Management with Immunotherapies
